Literature DB >> 22822113

Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?

Yuanyuan Liang1, Fei Du, Ian M Thompson, Barbara J Turner.   

Abstract

BACKGROUND: No previous study has examined racial ethnic differences in prostate-specific antigen (PSA) testing and followup in primary care practices serving an indigent population.
METHODS: From electronic medical records of primary care practices affiliated with one health care system in San Antonio, we identified 9,267 men aged 50 to 74 with 2+ clinic visits from 2008 through 2010 and no prior prostate cancer diagnosis. Logistic regression was used to examine the association of race ethnicity with the use of PSA testing and, if tested, with an abnormal result (≥4 ng/mL) adjusted for demographics, health care, and clinical factors. Time to a follow-up activity after an abnormal PSA was assessed using Cox proportional models.
RESULTS: The race ethnicity of this cohort was 63% Hispanic, 27% non-Hispanic white, 7% African-American, and 3% other. In a 3-year period, 26.8% of men had at least one PSA test. Compared with African-Americans, non-Hispanic whites were less likely to be tested [OR, 0.68; 95% confidence interval (CI), 0.55-0.83] but Hispanics did not differ (OR = 0.95; 95% CI 0.79-1.15). African-Americans were more likely to have an abnormal PSA than others (12.4% vs. 5.2%, P < 0.001) and the shortest adjusted time to follow-up (P = 0.004).
CONCLUSIONS: In this 3-year indigent cohort, about one quarter had a PSA test, approximately half of the national testing rate. IMPACT: African-Americans were more likely to be tested than non-Hispanic whites but had more abnormal results, raising concerns about missed prevention opportunities. African-Americans with high PSA results had the shortest time until follow-up, reflecting awareness of the threat of prostate cancer for African-Americans by physicians. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22822113      PMCID: PMC3436949          DOI: 10.1158/1055-9965.EPI-12-0497

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  26 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Prostate cancer screening between low-income African-American and Caucasian men.

Authors:  Jay H Fowke; David Schlundt; Lisa B Signorello; Flora A M Ukoli; William J Blot
Journal:  Urol Oncol       Date:  2005 Sep-Oct       Impact factor: 3.498

3.  Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy.

Authors:  Cynthia So; Katharine A Kirby; Kala Mehta; Richard M Hoffman; Adam A Powell; Stephen J Freedland; Brenda Sirovich; Elizabeth M Yano; Louise C Walter
Journal:  J Gen Intern Med       Date:  2011-12-17       Impact factor: 5.128

4.  Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council.

Authors:  E D Crawford; E P DeAntoni; R Etzioni; V C Schaefer; R M Olson; C A Ross
Journal:  Urology       Date:  1996-06       Impact factor: 2.649

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Explaining the race difference in prostate cancer stage at diagnosis.

Authors:  Beth A Jones; Wen-Liang Liu; Andre B Araujo; Stanislav V Kasl; Stephanie N Silvera; Hosanna Soler-Vilá; Mary G M Curnen; Robert Dubrow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09-30       Impact factor: 4.254

8.  Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Authors:  Louie E Ross; Zahava Berkowitz; Donatus U Ekwueme
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-03       Impact factor: 4.254

9.  Screening for prostatic carcinoma with prostate specific antigen.

Authors:  M K Brawer; M P Chetner; J Beatie; D M Buchner; R L Vessella; P H Lange
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Authors:  Brenda E Sirovich; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

View more
  3 in total

1.  Ethnic differences and predictors of colonoscopy, prostate-specific antigen, and mammography screening participation in the multiethnic cohort.

Authors:  Brook E Harmon; Melissa A Little; Erica D Woekel; Reynolette Ettienne; Camonia R Long; Lynne R Wilkens; Loic Le Marchand; Brian E Henderson; Laurence N Kolonel; Gertraud Maskarinec
Journal:  Cancer Epidemiol       Date:  2014-03-22       Impact factor: 2.984

Review 2.  What is appropriate care? An integrative review of emerging themes in the literature.

Authors:  Joelle Robertson-Preidler; Nikola Biller-Andorno; Tricia J Johnson
Journal:  BMC Health Serv Res       Date:  2017-06-30       Impact factor: 2.655

3.  Exposure to High Precariousness Prevalence Negatively Impacts Drug Prescriptions of General Practitioners to Precarious and Non-Precarious Populations: A Retrospective Pharmaco-Epidemiological Study.

Authors:  François Birault; Lakshmipriva Le Bonheur; Nicolas Langbour; Sandivanie Clodion; Nematollah Jaafari; Marie-Christine Perault-Pochat; Bérangère Thirioux
Journal:  Int J Environ Res Public Health       Date:  2022-03-03       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.